ScreenPoint

Netherlands-based ScreenPoint Medical has developed cutting-edge artificial intelligence technology to improve early detection of breast cancer.

Using Machine Learning techniques, it collects and interprets radiological data to provide radiologists with accurate and accessible analysis. This system not only reduces radiologists' workload, but also improves the quality of diagnoses.

Founded in 2014 by Nico Karssemeijer and Michael Brady, specialists in breast imaging, Machine Learning and computer-aided detection, ScreenPoint Medical has assembled a team of experts from the outset to develop a decision-support algorithm. Their main objective is to facilitate early detection of breast cancer in order to improve chances of survival and promote less invasive treatments, with the ultimate goal of saving lives.

ScreenPoint Medical's main product, Transpara Breast AI, has been trained on a large dataset comprising one million images and 15,000 cancer cases from various mammography models and medical centers. The algorithm's results are verified by confirmatory methods such as biopsy. To date, this artificial intelligence has analyzed over 5 million mammograms (2D and 3D) in more than 30 countries, in collaboration with radiologists.

To help interpret the results, ScreenPoint Medical has developed the Transpara Exam Score tool, which assesses cancer risk on a 10-point scale. Clinical research has shown that scores of 1 to 7, indicating a low risk on the scale, have a negative predictive value of 99.97%.

The company is experiencing significant growth, with 67 employees and annual recurring revenues of $13.6 million.

Every year in France, over 50,000 cases of breast cancer are diagnosed, underlining the importance of innovative solutions like those developed by ScreenPoint Medical, while over 4.4 million mammograms are performed for screening purposes.

‍